Highly active antiretroviral therapy and the incidence of HIV-1-associated nephropathy: A 12-year cohort study

AIDS

Volumn 18, Issue 3, 2004, Pages 541-546

  Lucas, Gregory M ^a,c   Eustace, Joseph A ^a   Sozio, Stephen ^a   Mentari, Evelyn K ^a   Appiah, Kofi A ^b   Moore, Richard D ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b GOOD SAMARITAN HOSPITAL   (United States)

^c NONE   (United States)

Author keywords

Highly active antiretroviral therapy; HIV 1; HIV 1 associated nephropathy

Indexed keywords

ANTIRETROVIRUS AGENT; NUCLEOSIDE DERIVATIVE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AFRICAN AMERICAN; ARTICLE; ASSOCIATION; COHORT ANALYSIS; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION ASSOCIATED NEPHROPAHTY; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFECTION RISK; KIDNEY BIOPSY; KIDNEY DISEASE; KIDNEY INFECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MULTIVARIATE ANALYSIS; PATIENT SELECTION; POISSON DISTRIBUTION; PRIORITY JOURNAL; REDUCTION; REGRESSION ANALYSIS; SIDE EFFECT; STATISTICAL SIGNIFICANCE;

ADULT; AIDS-ASSOCIATED NEPHROPATHY; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; FEMALE; HIV-1; HUMANS; INCIDENCE; MALE; MARYLAND; RISK FACTORS;

EID: 1642401131     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200402200-00022     Document Type: Article

References (26)

1. Rao TKS. Clinical features of human immunodeficiency virus associated nephropathy. Kidney Int 1991, 40(Suppl. 35): S13-S18.
2. Lee H, Manns B, Taub K, Ghali WA, Dean S, Johnson D, et al. Cost analysis of ongoing care of patients with end-stage renal disease: the impact of dialysis modality and dialysis access. Am J Kidney Dis 2002, 40:611-622.
3. Dave MB, Shabih K, Blum S. Maintenance hemodialysis in patients with HIV-associated nephropathy. Clin Nephrol 1998, 50:367-374.
4. Rao TK, Friedman EA, Nicastri AD. The types of renal disease in the acquired immunodeficiency syndrome. N Engl J Med 1987, 316:1062-1068.
5. Ahuja TS, Grady J, Khan S. Changing trends in the survival of dialysis patients with human immunodeficiency virus in the United States. J Am Soc Nephrol 2002, 13:1889-1893.
6. Shahinian V, Rajaraman S, Borucki M, Grady J, Hollander WM, Ahuja TS. Prevalence of HIV-associated nephropathy in autopsies of HIV-infected patients. Am J Kidney Dis 2000, 35: 884-888.
7. Winston JA, Klotman ME, Klotman PE. HIV-associated nephropathy is a late, not early, manifestation of HIV-1 infection. Kidney Int 1999, 55:1036-1040.
8. US Renal Data System (USRDS). USRDS 2000 Annual Data Report. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health; 2000.
9. UNAIDS. Report on the Global HIV/AIDS Epidemic, July 2002. Available at http://www.unaids.org. Last accessed December 2002.
10. Monahan M, Tanji N, Klotman PE. HIV-associated nephropathy: an urban epidemic. Semin Nephrol 2001, 21:394-402.
11. Wali RK, Drachenberg CI, Papadimitriou JC, Keay S, Ramos E. HIV-1-associated nephropathy and response to highly-active antiretroviral therapy. Lancet 1998, 352:783-784.
12. Szczech LA, Edwards LJ, Sanders LL, van der HC, Bartlett JA, Heald AE, et al. Protease inhibitors are associated with a slowed progression of HIV-related renal diseases. Clin Nephrol 2002, 57:336-341.
13. Winston JA, Bruggeman LA, Ross MD, Jacobson J, Ross L, D'Agati VD, et al. Nephropathy and establishment of a renal reservoir of HIV type 1 during primary infection. N Engl J Med 2001, 344:1979-1984.
14. Cosgrove CJ, Abu-Alfa AK, Perazella MA. Observations on HIV-associated renal disease in the era of highly active antiretroviral therapy. Am J Med Sci 2002, 323:102-106.
15. Eustace JA, Nuermberger E, Choi M, Scheel PJ, Jr., Moore R, Briggs WA. Cohort study of the treatment of severe HIV-associated nephropathy with corticosteroids. Kidney Int 2000, 58:1253-1260.
16. Smith MC, Austen JL, Carey JT, Emancipator SN, Herbener T, Gripshover B, et al. Prednisone improves renal function and proteinuria in human immunodeficiency virus-associated nephropathy. Am J Med 1996, 101:41-48.
17. Burns GC, Paul SK, Toth IR, Sivak SL. Effect of angiotensin-converting enzyme inhibition in HIV-associated nephropathy. J Am Soc Nephrol 1997, 8:1140-1146.
18. Moore RD. Understanding the clinical and economic outcomes of HIV therapy: The Johns Hopkins HIV clinical practice cohort J Acquir Immune Defic Syndr 1998, 17(suppl. 1):S38-S41.
19. D'Agati V, Appel GB. Renal pathology of human immunodeficiency virus infection. Semin Nephrol 1998, 18:406-421.
20. Centers for Disease Control and Prevention. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 1992, 41 (RR-17):1-19.
21. U.S. Renal Data System. USRDS 2002 Annual Data Report: Atlas of End-stage-renal Diseases in the United States. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health; 2002.
22. Bruggeman LA, Dikman S, Meng C, Quaggin SE, Coffman TM, Klotman PE. Nephropathy in human immunodeficiency virus-1 transgenic mice is due to renal transgene expression. J Clin Invest 1997, 100:84-92.
23. Kimmel PL. The nephropathies of HIV infection: pathogenesis and treatment Curr Opin Nephrol Hypertens 2000, 9:117-122.
24. Szczech LA, Gange SJ, van der HC, Bartlett JA, Young M, Cohen MH, et al. Predictors of proteinuria and renal failure among women with HIV infection. Kidney Int. 2002, 61:195-202.
25. Freedman BI, Soucie JM, Stone SM, Pegram S. Familial clustering of end-stage renal disease in blacks with HIV-associated nephropathy. Am J Kidney Dis 1999, 34:254-258.
26. Department of Health and Human Services and Henry J. Kaiser Family Foundation. Guidelines for the Use of Antiretroviral Agents in HIV-infected Adults and Adolescents. Available at http://www.hivatis.org. Last accessed December 2002.